NCT07225556

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	LY4167586	Administered SC
DRUG	Placebo	Administered SC
DRUG	LY4167586	Administered IV

Timeline

• Start date: 2025-11-18
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-11-06
• Last updated: 2026-03-09

Locations

2 sites across 2 countries: United States, Singapore

Regulatory

• FDA-regulated drug study